Journal Of Drug Targeting SCIE

國際簡稱：J DRUG TARGET 參考譯名：藥物靶向雜志

主要研究方向：醫(yī)學(xué)-藥學(xué) 非預(yù)警期刊審稿周期：約2月

《藥物靶向雜志》(Journal Of Drug Targeting)是一本由Informa Healthcare出版的以醫(yī)學(xué)-藥學(xué)為研究特色的國際期刊，發(fā)表該領(lǐng)域相關(guān)的原創(chuàng)研究文章、評論文章和綜述文章，及時(shí)報(bào)道該領(lǐng)域相關(guān)理論、實(shí)踐和應(yīng)用學(xué)科的最新發(fā)現(xiàn)，旨在促進(jìn)該學(xué)科領(lǐng)域科學(xué)信息的快速交流。該期刊是一本未開放期刊，近三年沒有被列入預(yù)警名單。

4區(qū) 中科院分區(qū)
Q1 JCR分區(qū)
69 年發(fā)文量
4.3 IF影響因子
未開放 是否OA
80 H-index
1993 創(chuàng)刊年份
Bimonthly 出版周期
English 出版語言

Journal of Drug Targeting publishes papers and reviews on all aspects of drug delivery and targeting for molecular and macromolecular drugs including the design and characterization of carrier systems (whether colloidal, protein or polymeric) for both vitro and/or in vivo applications of these drugs.

Papers are not restricted to drugs delivered by way of a carrier, but also include studies on molecular and macromolecular drugs that are designed to target specific cellular or extra-cellular molecules. As such the journal publishes results on the activity, delivery and targeting of therapeutic peptides/proteins and nucleic acids including genes/plasmid DNA, gene silencing nucleic acids (e.g. small interfering (si)RNA, antisense oligonucleotides, ribozymes, DNAzymes), as well as aptamers, mononucleotides and monoclonal antibodies and their conjugates. The diagnostic application of targeting technologies as well as targeted delivery of diagnostic and imaging agents also fall within the scope of the journal. In addition, papers are sought on self-regulating systems, systems responsive to their environment and to external stimuli and those that can produce programmed, pulsed and otherwise complex delivery patterns.

[ 查看全部 ]

投稿咨詢加急咨詢

Journal Of Drug Targeting期刊信息

ISSN：1061-186X
出版語言：English
是否OA：未開放
E-ISSN：1029-2330
出版地區(qū)：ENGLAND
是否預(yù)警：否
出版商：Informa Healthcare
出版周期：Bimonthly
創(chuàng)刊時(shí)間：1993
開源占比：0.0198
Gold OA文章占比：2.21%
OA被引用占比：0.0238...
出版國人文章占比：0.32
出版撤稿占比：0
研究類文章占比：44.93%

Journal Of Drug Targeting CiteScore評價(jià)數(shù)據(jù)（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指數(shù)

9.1

0.849

0.706

學(xué)科類別	分區(qū)	排名	百分位
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Pharmaceutical Science	Q1	23 / 183	87%

名詞解釋：CiteScore 是衡量期刊所發(fā)表文獻(xiàn)的平均受引用次數(shù)，是在 Scopus 中衡量期刊影響力的另一個(gè)指標(biāo)。當(dāng)年CiteScore 的計(jì)算依據(jù)是期刊最近4年（含計(jì)算年度）的被引次數(shù)除以該期刊近四年發(fā)表的文獻(xiàn)數(shù)。例如，2022年的 CiteScore 計(jì)算方法為：2022年的 CiteScore =2019-2022年收到的對2019-2022年發(fā)表的文件的引用數(shù)量÷2019-2022年發(fā)布的文獻(xiàn)數(shù)量注：文獻(xiàn)類型包括：文章、評論、會(huì)議論文、書籍章節(jié)和數(shù)據(jù)論文。

Journal Of Drug Targeting中科院評價(jià)數(shù)據(jù)

中科院 2023年12月升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	4區(qū)	PHARMACOLOGY & PHARMACY 藥學(xué)	4區(qū)

中科院 2022年12月升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	PHARMACOLOGY & PHARMACY 藥學(xué)	3區(qū)

中科院 2021年12月舊的升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	PHARMACOLOGY & PHARMACY 藥學(xué)	3區(qū)

中科院 2021年12月基礎(chǔ)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	PHARMACOLOGY & PHARMACY 藥學(xué)	3區(qū)

中科院 2021年12月升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	PHARMACOLOGY & PHARMACY 藥學(xué)	3區(qū)

中科院 2020年12月舊的升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	4區(qū)	PHARMACOLOGY & PHARMACY 藥學(xué)	4區(qū)

Journal Of Drug Targeting JCR評價(jià)數(shù)據(jù)（2023-2024年最新版）

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：PHARMACOLOGY & PHARMACY	SCIE	Q1	69 / 354	80.6%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：PHARMACOLOGY & PHARMACY	SCIE	Q2	94 / 354	73.59%

Journal Of Drug Targeting歷年數(shù)據(jù)統(tǒng)計(jì)

影響因子

中科院分區(qū)

Journal Of Drug Targeting中國學(xué)者發(fā)文選摘

1、TGF beta 1/integrin beta 3 positive feedback loop contributes to acquired EGFR TKI resistance in EGFR-mutant lung cancer
Author: Wang, Tao; Zhang, Yali; Cheng, Hanyue; Li, Ling; Xu, Lu

Journal: JOURNAL OF DRUG TARGETING. 2023; Vol. 31, Issue 3, pp. 269-277. DOI: 10.1080/1061186X.2022.2064480
2、Macrophage membrane biomimetic drug delivery system: for inflammation targeted therapy
Author: Zhang, Yulu; Long, Yu; Wan, Jinyan; Liu, Songyu; Shi, Ai; Li, Dan; Yu, Shuang; Li, Xiaoqiu; Wen, Jing; Deng, Jie; Ma, Yin; Li, Nan

Journal: JOURNAL OF DRUG TARGETING. 2023; Vol. 31, Issue 3, pp. 229-242. DOI: 10.1080/1061186X.2022.2071426
3、Mucus- and pH-mediated controlled release of core-shell chitosan nanoparticles in the gastrointestinal tract for diabetes treatment
Author: Shi, Yanan; Liu, Lanze; Yin, Miaomiao; Zhao, Zhenyu; Liang, Yanzi; Sun, Kaoxiang; Li, Youxin

Journal: JOURNAL OF DRUG TARGETING. 2023; Vol. 31, Issue 1, pp. 65-73. DOI: 10.1080/1061186X.2022.2104296
4、Advances, challenge and prospects in cell-mediated nanodrug delivery for cancer therapy: a review
Author: Wei, Wuhao; Zhang, Yuansheng; Lin, Zhizhe; Wu, Xin; Fan, Wei; Chen, Jianming

Journal: JOURNAL OF DRUG TARGETING. 2023; Vol. 31, Issue 1, pp. 1-13. DOI: 10.1080/1061186X.2022.2104299
5、Poly-gamma-glutamic acid coating polymeric nanoparticles enhance renal drug distribution and cellular uptake for diabetic nephropathy therapy
Author: Wang, Qili; Han, Shunping; Zhu, Yongqin; Wang, Guowei; Chen, Danfei

Journal: JOURNAL OF DRUG TARGETING. 2023; Vol. 31, Issue 1, pp. 89-99. DOI: 10.1080/1061186X.2022.2106488
6、Nano-composite hydrogels of Cu-Apa micelles for anti-vasculogenic mimicry
Author: Kang, Rui; Song, Mengdi; Fang, Zhou; Liu, Kehai

Journal: JOURNAL OF DRUG TARGETING. 2023; Vol. 31, Issue 2, pp. 166-178. DOI: 10.1080/1061186X.2022.2115047
7、Progress in research and development of temozolomide brain-targeted preparations: a review
Author: Yang, Jiefen; Xu, Youfa; Fu, Zhiqin; Chen, Jianming; Fan, Wei; Wu, Xin

Journal: JOURNAL OF DRUG TARGETING. 2023; Vol. 31, Issue 2, pp. 119-133. DOI: 10.1080/1061186X.2022.2119243
8、Transdermal delivery of celecoxib and alpha-linolenic acid from microemulsion-incorporated dissolving microneedles for enhanced osteoarthritis therapy
Author: Li, Jian; Tian, Xin; Wang, Kang; Jia, Yong; Ma, Fuguang

Journal: JOURNAL OF DRUG TARGETING. 2023; Vol. 31, Issue 2, pp. 206-216. DOI: 10.1080/1061186X.2022.2123492